Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors

This study has been terminated.
(Data analysis)
Information provided by (Responsible Party):
Anne Chang, Stanford University Identifier:
First received: October 11, 2011
Last updated: December 2, 2013
Last verified: December 2013

This is a prospective single-center, open label, pilot study to investigate the safety and efficacy of LDE225 in patients with locally advanced or metastatic basal cell carcinoma.

Primary Objectives:

• To explore the effects of oral LDE225 on the Progression Free Survival (PFS) of individuals with locally advanced or metastatic BCC who have been previously treated with a non-LDE225 Smo inhibitor.

Secondary Objectives:

  • To evaluate the effect of oral LDE225 on tumor tissue biomarkers of BCC activation (Gii 1, 2, Patched 1,2 and Ki67) in individuals which are non-na"ive to Smo inhibitors other than LDE225, at baseline and at end-of-treatment
  • To describe adverse effects of oral LDE225 in individuals with a history of non-LDE225 Smo inhibitor usage
  • To assess the overall survival rates of individuals with locally advanced BCC or metastatic BCC who have previously taken a non-LDE225 Smo inhibitor after treatment with LDE225

Condition Intervention
Basal Cell Carcinoma
Drug: LDE225

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Open-Label Study to Examine the Safety and Efficacy of Oral LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Who Have Been Previously Treated With Non-LDE225 Smoothened Inhibitor(s)

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Progression Free Survival (PFS) of individuals with locally advanced or metastatic BCC who have been previously treated with a non-LDE225 Smo inhibitor [ Time Frame: End of Treatment or 12 months whichever comes first ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Biomarker levels of oral LDE225 on tumor tissue biomarkers of BCC activation (Gli 1, 2, Patched 1,2 and Ki67) in individuals which are non-naïve to Smo inhibitors other than LDE225 [ Time Frame: End of treatment or 12 months whichever comes first ] [ Designated as safety issue: No ]

Enrollment: 11
Study Start Date: February 2012
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Refractory Group
Patients previously treated with non-LDE225 Smo inhibitor who were refractory.
Drug: LDE225
800-mg (4 200-mg capsules/day) capsule
Other Name: NVP-LDE225
Active Comparator: Resistance Developed Group
Patients previously treated with non-LDE225 Smo inhibitor who were initially responsive but became resistant with progressive disease.
Drug: LDE225
800-mg (4 200-mg capsules/day) capsule
Other Name: NVP-LDE225


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18 years or older.
  2. Histologically documented diagnosis of basal cell carcinoma deemed to be locally advanced or metastatic who have previously received a non-LDE225 Smo inhibitor.
  3. WHO performance status <= 2
  4. At least one measurable site of disease (as defined by Response Evaluation Criteria in Solid Tumors), or other disease specific response assessment criteria, as appropriate. State age restriction and/or gender/race-ethnic restrictions.
  5. Patients with adequate bone marrow, liver and renal function, as specified below:

    • Absolute Neutrophil Count (ANC) >= 1.5 x 10^9/L
    • Hemoglobin (Hgb) >= 9 g/dL
    • Platelets >= 80 x 10^9/L
    • Serum total bilirubin <= 1.5 x ULN(upper limit of normal)
    • AST and ALT <= 2.5 x ULN or <= 5 x ULN if liver metastases are present
    • Plasma creatine phosphokinase (CK) < 1.5 x ULN
    • Serum creatinine <= 1.5 x ULN or 24-hour clearance >= 50ml/min
  6. Written informed consent obtained prior to any screening procedures

Exclusion Criteria:

  1. Patients who have had major surgery within 4 weeks of initiation of study medication.
  2. Patients with concurrent uncontrolled medical conditions that may interfere with their participation in the study or potentially affect the interpretation of the study data.

    State restrictions regarding use of other Investigational Agents.

  3. Patients unable to take oral drugs or with lack of physical integrity of the upper gastrointestinal tract or known malabsorption syndromes.

    State exclusion requirements due to co-morbid disease or incurrent illness, as needed.

  4. Patients who have previously been treated with systemic LDE225.
  5. Patients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as HMG CoA inhibitors (statins), clofibrate and gemfibrozil, and that cannot be discontinued at least 2 weeks prior to starting LDE225 treatment. If it is essential that the patient stays on a statin to control hyperlipidemia, only pravastatin may be used with extra caution.

    b) Patients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment. NB: Muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided whilst on LDE225 treatment.

  6. Patients who have taken part in an experimental drug study within 4 weeks of initiating treatment with LDE225.
  7. Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within 2 weeks of starting treatment with LDE225.
  8. Patients who are receiving treatment with medications known to be moderate and strong inhibitors or inducers of CYP3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that have narrow therapeutic index, and that cannot be discontinued before starting treatment with LDE225. Medications that are strong CYP3A4/5 inhibitors should be discontinued at least 7 days and strong CYP3A/5 inducers for at least 2 weeks prior to starting treatment with LDE225.
  9. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL).

10 Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. Adequate barrier methods of contraception include:

  • Diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent.
  • Reliable contraception should be maintained throughout the study and for 3 months after study drug discontinuation.

    11 Patients unwilling or unable to comply with the protocol.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01529450

United States, California
Stanford University Cancer Institute
Stanford, California, United States, 94305
Sponsors and Collaborators
Anne Chang
Principal Investigator: Anne Chang, MD Stanford University
  More Information

No publications provided

Responsible Party: Anne Chang, Assistant Professor of Dermatology, Stanford University Identifier: NCT01529450     History of Changes
Other Study ID Numbers: SKIN0009, SU-09022011-8371, 21759
Study First Received: October 11, 2011
Last Updated: December 2, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma, Basal Cell
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Neoplasms, Glandular and Epithelial processed this record on November 20, 2014